{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-000453","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.933236+00:00","generated_at":"2026-05-28T00:49:14.968295+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate","bullets":["Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.","To date, completed exchanges with two investors for 14,200 shares of common stock.","Director Laith Yaldoo manages two entities expected to participate in the Exchange Program.","Exchange eliminates investor rights to future revenue share cash and a $5.3M buy-out option.","Investors retain Warrants issued under the original Participation Agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-000453","json":"https://secwatch.observer/filing/0001654954-25-000453.json","markdown":"https://secwatch.observer/filing/0001654954-25-000453.md","text":"https://secwatch.observer/filing/0001654954-25-000453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000453/0001654954-25-000453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000453/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T00:49:14.968295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}